In The News
Clyde & Co sued by insurers over indemnity advice
Union boss says she faces charges over alleged $2.7M scheme, wants FWC case stayed
Law firm report clears WiseTech founder Richard White of misconduct
Second judge has rosier view of claims in class action over $85M development
Pharmacor says AstraZeneca’s Brilinta patent should not have been extended
Russells partner accused of bullying told lawyer she was ‘very negative’
‘Our integrations are on track’: Class action flags WiseTech response to short seller report
Cornwalls hits back at $4.8M negligence suit by former client
Top silk to join NSW Supreme Court
NAB accused of rescinding job offer to pregnant employee
Please login to bookmarkClose

ASX-listed generic drug maker Mayne Pharma is facing a possible shareholder class action over disclosures related to US price-fixing allegations against the ASX-listed company.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au